Author

E. Gerhard-Hartmann

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Rosenwald· 2 shared A. Cosma· 1 shared A. Floerchinger· 1 shared A. Maiques-Diaz· 1 shared A. Moore· 1 shared C. DSantos· 1 shared C. S. Chilamakuri· 1 shared C. Schifflers· 1 shared

Activity by Year

2021-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. Rosenwald

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

High-dimensional single-cell definition of CLL T cells identifies Galectin-9 as novel immunotherapy target

L. L. Cid, J. K. Leong, I. F. Botana, Y. Paul, M. Wierz, A. Floerchinger, S. Gonder, G. Pagano, M. Chazotte, K. Bestak, C. Schifflers, M. Iskar, T. Roider, F. Czernilofsky, P.-M. Bruch, , M. Seiffert

The paper defines CLL T cell subtypes and identifies Galectin-9 as a novel immunotherapy target through single-cell and multi-omics analyses.

bioRxiv · Dec 15, 2022 · PreprintCancer Biology

NOTCH1 drives immune-escape mechanisms in B cell malignancies

M. Mangolini, A. Maiques-Diaz, S. Charalampopoulou, E. Gerhard-Hartmann, J. Bloehdorn, A. Moore, J. Lu, V. N. Roamio Franklin, C. S. Chilamakuri, I. Moutsoupoulos, A. Rosenwald, S. Stilgenbauer, T. Zenz, I. Mohorianu, C. DSantos, , I. Ringshausen

This study shows NOTCH1 mutations in B cell malignancies promote immune escape by upregulating PD-L1 and silencing HLA-class II, leading to poor clinical outcomes.

bioRxiv · Apr 10, 2021 · PreprintCancer Biology